Evidence map›Paper›PMID 29222719›Full record

Trial reportGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2018

Longevity of visual improvements following transcorneal electrical stimulation and efficacy of retreatment in three individuals with retinitis pigmentosa.

Ava K Bittner, Kenneth Seger

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02086890 (Modulating Ocular/Retinal Blood Flow and Visual Function in Retinitis Pigmentosa), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02086890 naactive not recruitingnot on this map

Modulating Ocular/Retinal Blood Flow and Visual Function in Retinitis Pigmentosa

TypeinterventionalSponsorNova Southeastern UniversityRan2014 to 2027Enrolled21ConditionsRetinitis PigmentosaArmsElectro-acupuncture, Laser Acupuncture, Transcorneal Electrical Stimulation, Sham Electro-acupuncture, Sham laser acupuncture
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Current Approaches to Low Vision (Re)HabilitationTurkish journal of ophthalmology · 2019
    Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ava K BittnerNova Southeastern University, College of Optometry, 3200 S. University Drive, Fort Lauderdale, FL, 33328, USA. abittne1@jhmi.edu.
Kenneth SegerNova Southeastern University, College of Optometry, 3200 S. University Drive, Fort Lauderdale, FL, 33328, USA.
Nova Southeastern University · US

Funding

Modulating Ocular/Retinal Blood Flow and Visual Function in Retinitis PigmentosaR21EY023720 · NEI · NOVA SOUTHEASTERN UNIVERSITY · PI BITTNER, AVA K · 2013 to 2013
$227k
National Eye Institute EY023720NEI NIH HHS R21 EY023720Nova Southeastern University PFRDG
6 · The paper itself

Abstract

purposeA small-scale randomized controlled trial conducted by our group found that four of seven retinitis pigmentosa (RP) subjects who received six weekly Transcorneal Electrical Stimulation (TES) sessions developed significant improvements in visual acuity (VA), quick contrast sensitivity function (qCSF), and/or Goldmann visual fields (GVF). We longitudinally monitored three of these participants for declining visual function due to natural RP progression to determine the duration of their responses and administered retreatments.

methodsOver a period of 29-35 months, repeated ETDRS VA, qCSF and/or GVF tests and three to six TES treatment courses consisting of six weekly sessions were administered in each eye of three RP participants every four to 16 months in an unmasked, prospective case series study.

resultsFor two participants, there were significant VA improvements of 44-52 letters (0.88-1.04 logMAR) and 15-23 letters (0.3-0.46 logMAR) in the worse eye at baseline after each of three or four treatment courses of TES compared to initial baseline. They had no significant decreases from baseline for VA or qCSF over 29 to 35 months, The third participant had a significant mean improvement in VA in the eye with better baseline vision (p = 0.004) and binocularly (p < 0.001) following six treatment courses over the 29-month period. For the first two participants, mean annual rates of GVF change for each eye ranged from -5% to 0% with the V4e stimulus, and -26% to +33% the III4e stimulus. The third participant's mean annual GVF changes were +14 to +35%, with a statistically significant improvement across 29 months for both the V4e and III4e stimuli in the right eye (p = 0.045; p = 0.015) and the V4e stimulus in the left eye (p = 0.047).

conclusionFollowing encouraging visual improvements after TES that lasted for several months, it appears it may be possible to restore and prevent slowly diminishing vision over time with retreatments, which requires confirmation in a large-scale randomized controlled trial.

Indexed as

Visual AcuityVisual FieldsAdultContrast SensitivityCorneaDouble-Blind MethodElectric StimulationFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRetinaRetinitis PigmentosaRetreatmentContrast sensitivityGoldmann visual fieldRetinitis pigmentosaTranscorneal electrical stimulationVisual acuity

Identifiers

PMID29222719
PMCPMC6039224
OpenAlexW2771469080

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.